The FDA has extended its review of the ProSense cryoablation system for early-stage breast cancer, with a decision expected ...

Cryoablation, the destruction of malignant cancer cells by freezing them, is increasingly becoming an alternative to having ...

Research reveals men skipping prostate cancer screenings are 45% more likely to die from the disease. Evidence from a large ...

IceCure Medical (ICCM) announced that interim results from the Company’s ICESECRET study of cryoablation for patients with small renal masses ...

(Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal ...

IceCure Medical Ltd. ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor ...

A study led by UCLA investigators shows that artificial intelligence (AI) could play a key role in improving treatment outcomes for men with prostate cancer by helping physicians determine who is most ...

A new artificial intelligence tool could help doctors determine which prostate cancer patients are most likely to benefit ...

A new UCLA study has found that artificial intelligence could help doctors identify prostate cancer patients most ...

Fusion biopsy and patient follow-up with 3D mapping are the cornerstone of a successful Focal Therapy program. In line with ...